Patents by Inventor Diondra D. Hill

Diondra D. Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER
    Publication number: 20160003825
    Abstract: The present invention provides use of protein kinase C-zeta (PKC-?) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Applicants: University of South Florida, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Mildred Enid Acevedo-Duncan, Diondra D. Hill
  • Method of selectively inhibiting PKCiota
    Patent number: 8461192
    Abstract: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?,2?,3?,4?)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: June 11, 2013
    Assignees: The University of South Florida, The United States of America Department of Veterans Affairs, The University of Florida Research Foundation, Inc.
    Inventors: Mildred Acevedo-Duncan, Shraddha R. Desai, Hla Yee Win, David A. Ostrov, Prajit P. Pillai, Diondra D. Hill
  • USE OF PKC-ZETA AS A BREAST CANCER TUMORIGENIC BIOMARKER AS WELL AS A TARGET FOR TREATMENT OF BREAST CANCER
    Publication number: 20120171219
    Abstract: The present invention provides use of protein kinase C-zeta (PKC-?) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.
    Type: Application
    Filed: December 1, 2011
    Publication date: July 5, 2012
    Applicants: United States Department of Veterans Affairs, University of South Florida
    Inventors: Mildred Acevedo-Duncan, Diondra D. Hill
  • METHOD OF SELECTIVELY INHIBITING PKCiota
    Publication number: 20090075932
    Abstract: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?,2?,3?,4?)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.
    Type: Application
    Filed: September 15, 2008
    Publication date: March 19, 2009
    Applicants: UNIVERSITY OF SOUTH FLORIDA, UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Mildred Acevedo-Duncan, Shraddha R. Desai, Hla Yee Win, David A. Ostrov, Prajit P. Pillai, Diondra D. Hill